

1  
2  
3  
4  
5 UNITED STATES DISTRICT COURT  
6 WESTERN DISTRICT OF WASHINGTON  
7

8 MARIA OLIVIA AGUILAR,  
9 Plaintiff,  
10 v.  
11 AMERICAN MEDICAL SYSTEMS,  
12 INC.  
13 Defendant.

No. 2:20-CV-00259-SAB

**ORDER GRANTING IN PART  
AND DENYING IN PART  
DEFENDANT'S MOTION FOR  
SUMMARY JUDGMENT**

14  
15 Before the Court is Defendant's Motion for Summary Judgment, ECF No.  
16 24. A videoconference was held on November 2, 2020. Plaintiff was represented  
17 by Jonathan Orent. Defendant was represented by Regina Nelson and Anne  
18 Talcott.

19 Plaintiff initially filed her Complaint in the Southern District of West  
20 Virginia as part of the Multi-District Litigation proceedings, *In Re: American*  
21 *Medical Systems, Inc. Pelvic Repair System Products Liability Litigation, MDL*  
22 *2325*. ECF No. 1. Plaintiff asserts she was implanted with Defendant's Monarc  
23 Subfacial Hammock. *Id.* She is alleging sixteen counts, including (Ct. I)  
24 Negligence; (Ct. II) Strict Liability – Design Defect; (Ct. III) Strict Liability –  
25 Manufacturing Defect; (Ct. IV) Strict Liability – Failure to Warn; (Ct. V) Strict  
26 Liability – Defective Product; (Ct. VI) Breach of Express Warranty; (Ct. VII)  
27 Breach of Implied Warranty; (Ct. VIII) Fraudulent Concealment; (Ct. IX)  
28 Constructive Fraud; (Ct. X) Discovery Rule, Tolling and Fraudulent Concealment;

**ORDER GRANTING IN PART AND DENYING IN PART  
DEFENDANT'S MOTION FOR SUMMARY JUDGMENT ~ 1**

1 (Ct. XI) Negligent Misrepresentation; (Ct. XII) Negligent Infliction of Emotional  
2 Distress; (Ct. XIII) Violation of Consumer Protection Law; (Ct. XIV) Gross  
3 Negligence; (Ct. XV) Unjust Enrichment; and (Ct. XVII) Punitive Damages.

4 Defendant now moves for summary judgment on all of Plaintiff's claims. In  
5 her response, Plaintiff indicates she is withdrawing her claims relating to  
6 Manufacturing defects, Express and Implied Warranty, Fraudulent Concealment,  
7 Constructive Fraud, Negligent Misrepresentation, Negligent Infliction of  
8 Emotional Distress, Unjust Enrichment and violations of the Washington  
9 Consumer Protection laws. ECF No. 28. Based on this representation, the Court  
10 will grant Defendant's Motion for Summary Judgment with respect to Cts. I, III,  
11 V-XV. The Court dismisses any claims for punitive damages as these are not  
12 available for Washington Products Liability claims. *See Steele v. Johnson*, 76  
13 Wash.2d 750, 753 (1969) (holding punitive damages are not permitted under  
14 Washington law unless expressly permitted by statute). Thus, the remaining claims  
15 are Ct. II, Design Defect, and Ct. IV, Failure to Warn.

#### 16 **Motion Standard**

17 Summary judgment is appropriate "if the movant shows that there is no  
18 genuine dispute as to any material fact and the movant is entitled to judgment as a  
19 matter of law." Fed. R. Civ. P. 56(a). There is no genuine issue for trial unless  
20 there is sufficient evidence favoring the non-moving party for a jury to return a  
21 verdict in that party's favor. *Anderson v. Liberty Lobby, Inc.*, 477 U.S. 242, 250  
22 (1986). The moving party has the initial burden of showing the absence of a  
23 genuine issue of fact for trial. *Celotex Corp. v. Catrett*, 477 U.S. 317, 325 (1986).  
24 If the moving party meets its initial burden, the non-moving party must go beyond  
25 the pleadings and "set forth specific facts showing that there is a genuine issue for  
26 trial." *Anderson*, 477 U.S. at 248.

27 In addition to showing there are no questions of material fact, the moving  
28 party must also show it is entitled to judgment as a matter of law. *Smith v. Univ. of*

1 *Wash. Law Sch.*, 233 F.3d 1188, 1193 (9th Cir. 2000). The moving party is entitled  
2 to judgment as a matter of law when the non-moving party fails to make a  
3 sufficient showing on an essential element of a claim on which the non-moving  
4 party has the burden of proof. *Celotex*, 477 U.S. at 323. The non-moving party  
5 cannot rely on conclusory allegations alone to create an issue of material fact.  
6 *Hansen v. United States*, 7 F.3d 137, 138 (9th Cir. 1993).

7 When considering a motion for summary judgment, a court may neither  
8 weigh the evidence nor assess credibility; instead, “the evidence of the non-movant  
9 is to be believed, and all justifiable inferences are to be drawn in his favor.”  
10 *Anderson*, 477 U.S. at 255.

### 11 **Background Facts**

12 On June 30, 2008, Dr. Margaret L. Hutchinson performed an anterior  
13 colporrhaphy, posterior repair, Mirena IUD placement, labiaplasty and insertion of  
14 the Monarc Subfacial Hammock at Swedish Medical Center in Seattle,  
15 Washington. ECF No. 1. Plaintiff asserts the implant caused pain, erosion, urinary  
16 problems, recurrence, bleeding, dyspareunia and vaginal scarring. ECF No. 6.

### 17 **Washington Products Liability Act**

#### 18 **1. (Ct. IV) – Strict Liability Failure to Warn claim**

19 Plaintiff’s Failure to Warn claim falls under the Washington Product  
20 Liability Act (WPLA).<sup>1</sup> *Taylor v. Intuitive Surg., Inc.*, 187 Wash.2d 743, 754  
21 (2017) (“The WPLA governs product-related harm claims based on a  
22 manufacturer’s failure to warn.”). Section 7.72.080 provides, in part:

23 (1) A product manufacturer is subject to liability to a claimant if the  
24 claimant’s harm was proximately caused by the negligence of the  
25 manufacturer in that the product was not reasonably safe as designed

---

26  
27 <sup>1</sup> The parties agree that Washington substantive law applies to Plaintiff’s Failure to  
28 Warn claim.

1 or not reasonably safe because adequate warnings or instructions were  
2 not provided.

3 (b) A product is not reasonably safe because adequate  
4 warnings or instructions were not provided with the product, if, at the  
5 time of manufacture, the likelihood that the product would cause the  
6 claimant's harm or similar harms, and the seriousness of those harms,  
7 rendered the warnings or instructions of the manufacturer inadequate  
8 and the manufacturer could have provided the warnings or  
9 instructions which the claimant alleges would have been adequate.

10 (c) A product is not reasonably safe because adequate  
11 warnings or instructions were not provided after the product was  
12 manufactured where a manufacturer learned or where a reasonably  
13 prudent manufacturer should have learned about a danger connected  
14 with the product after it was manufactured. In such a case, the  
15 manufacturer is under a duty to act with regard to issuing warnings or  
16 instructions concerning the danger in the manner that a reasonably  
17 prudent manufacturer would act in the same or similar circumstances.  
18 This duty is satisfied if the manufacturer exercises reasonable care to  
19 inform product users.

20 Washington law follows the learned intermediary doctrine. *Taylor*, 187  
21 Wash.2d at 757. Under this doctrine, while the manufacturer has a duty to warn  
22 patients of product risks, it can satisfy this duty by properly warning the doctor (the  
23 learned intermediary), who then takes on the responsibility of communicating  
24 those warnings to the patient. *Terhune v. A.H. Robins Co.*, 90 Wash.2d 9, 17  
25 (1978).

#### 26 **a. Adequacy of the Warnings**

27 A manufacturer has a duty to provide warnings or instructions  
28 commensurate with its harm and the risk. *Estate of LaMontagne v. Bristol-Myers  
Squibb*, 127 Wash. App. 335, 345 (2005). Generally, the adequacy of a warning  
will be a question of fact. *Id.* at 343. However, a question of fact can be determined  
as a matter of law when reasonable minds can reach only one conclusion from the  
admissible evidence. *Id.* To determine whether a warning is adequate requires an  
analysis of the warnings as a whole and the language used in the package insert. *Id.*

1 at 344. The trier of fact must examine the meaning and context of the language and  
2 the manner of expression to determine if the warning is accurate, clear and  
3 consistent and whether the warning portrays the risks involved using the device. *Id.*

4 A plaintiff is not required to establish the exact wording of the alternative  
5 warning. *Ayers by and through Ayers v. Johnson & Johnson Baby Prod. Co.*, 117  
6 Wash.2d 747, 756 (1991). Requiring plaintiffs in failure to warn cases to establish  
7 the exact wording of an alternative warning would impose too onerous a burden.  
8 *Id.* The jury might agree that a certain type of warning should have been provided,  
9 but they might not agree among themselves as to exactly how that warning should  
10 have been worded. *Id.* The statute’s requirement that “the manufacturer could have  
11 provided the warnings or instructions which the claimant alleges would have been  
12 adequate” is satisfied if the plaintiff specifies the substance of the warning. *Id.*

13 Here, Plaintiff relies on the testimony of her general causation experts, Dr.  
14 Galloway, Dr. Parisian and Dr. Blavis, who have opined that the warnings were not  
15 adequate. This is enough to defeat summary judgment on the question as to  
16 whether the warnings were adequate.

#### 17 **b. Proximate Cause**

18 Under Washington law, “[i]n a products liability suit alleging inadequate  
19 warnings, the plaintiff must show that his or her injury was proximately caused by  
20 a product that was ‘not reasonably safe because adequate warnings or instructions  
21 were not provided.’” *Ayers*, 117 Wash.2d at 752. To show proximate causation, the  
22 plaintiff must show both cause in fact and legal causation. *Id.* (citation omitted).  
23 “Cause in fact refers to the actual connection between the act and an injury—but  
24 for the act, the injury would not have occurred.” *Sherman v. Pfizer, Inc.*, 8 Wash.  
25 App.2d 686, 687 (2019). Legal causation depends on considerations of “logic,  
26 common sense, justice, policy, and precedent.” *Ayers*, 117 Wash.2d. at 756.  
27 (quotation omitted). It involves the “determination of whether liability should  
28

1 attach as a matter of law given the existence of cause in fact.” *Id.* (quotation  
2 omitted).

3 Cause in fact is generally a question for the jury. *Baughn v. Honda Motor*  
4 *Co., Ltd.*, 107 Wash.2d 127, 142 (1986). When the facts are undisputed, however,  
5 so that an inference can be made that is incapable of reasonable doubt or difference  
6 of opinion, factual causation may be a question of law for the court. *Id.*

7 Defendant relies on the testimony of Dr. Hutchison, Plaintiff’s physician  
8 who implanted the device in question, to assert that Plaintiff is unable to establish  
9 causation based on an alleged inadequate warning. Dr. Hutchison testified that she  
10 was aware of the relevant risks when she implanted the Monarc in Plaintiff; she  
11 reviewed the published literature regarding the Monarc, and the risks of the  
12 Monarc were well known in the medical community. When asked if “knowing  
13 everything you know today about the Monarc, do you stand by your decision that  
14 you made in 2008 to use the Monarc to treat [Plaintiff’s] stress urinary  
15 incontinence?” Dr. Hutchison answered, “Yes.”

16 Defendant argues that Dr. Hutchison’s statements preclude Plaintiff from  
17 showing that a different, increased warning would have persuaded Dr. Hutchison  
18 to take a different course of action.

19 The Court disagrees with Defendant that Dr. Hutchison’s statement permits  
20 the Court, rather than the jury, to determine proximate cause. First, it is not clear  
21 from the record what Dr. Hutchison knew about the Monarc when she made her  
22 statement. Also, it is not clear from the record what risks were well known in the  
23 medical community. A reasonable jury would need to hear what Dr. Hutchison  
24 now knows about the Monarc before it can assess the significance of her statement  
25 regarding her decision. Dr. Hutchison’s answer to counsel’s question is not  
26 sufficient to take the proximate cause decision from the jury. Second, the Court  
27 does not consider Dr. Hutchison an unbiased witness. Thus, it will be important for  
28

1 the jury to hear and evaluate her testimony on both direct and cross-examination  
2 and determine her credibility.

3 Because genuine issues of material fact regarding whether the warnings  
4 provided by Defendant were adequate and whether the failure to provide adequate  
5 warnings proximately caused Plaintiff’s injuries, summary judgment on Plaintiff’s  
6 failure to warn claim is not appropriate.

## 7 **2. Strict Liability – Design Defect claim**

8 Under the Washington Product Liability Act, to show a product was  
9 defectively designed, a plaintiff must show that a manufacturer’s product was not  
10 reasonably safe as designed and caused harm to the plaintiff. Wash. Rev. Code §  
11 7.72.030.

12 “There is no debate” that Washington courts have expressly adopted the  
13 comment *k* exception to strict liability in the case of unavoidably unsafe products.  
14 *Ruiz–Guzman v. Amvac Chem. Corp.*, 141 Wash.2d 493, 506 (2000) (citation  
15 omitted). Moreover, the Ninth Circuit noted the Washington Supreme Court has  
16 indicated that comment *k* provides an exemption for medical products generally.  
17 *Transue v. Aesthetech Corp.*, 341 F.3d 911, 915 (9th Cir. 2003).<sup>2</sup> After reviewing  
18 \_\_\_\_\_

19 <sup>2</sup> The *Transue* court relied on the following cases: (1) In *Terhune*, the court found  
20 that the Dalkon Shield implanted contraceptive device qualified for comment *k*  
21 exemption because of its availability only through a physician. 90 Wash.2d 9  
22 (1978); (2) in *Rogers v. Miles Lab., Inc.*, the court held that blood and blood  
23 products qualify for comment *k* exemption. 116 Wash.2d 195 (1991) (en banc); (3)  
24 a plurality of the court in *Young v. Key Pharmaceuticals, Inc.*, held that “a separate  
25 determination of whether a product is unavoidably unsafe need not be made on a  
26 case-by-case basis if that product is a prescription drug.” 130 Wash.2d 160 (1996)  
27 (en banc); and (4) in *Ruiz–Guzman*, the court held that “[b]y its own terms,  
28 comment *k* is especially applicable to medical products. The exceptions for

1 Washington caselaw, the Circuit concluded that “if the Washington Supreme Court  
2 were to encounter this precise issue, the most reasonable inference from existing  
3 precedents is that it would likely follow its dicta in *Ruiz-Guzman* and hold that all  
4 medical devices and products will be afforded comment *k* exemption.” *Id.*

5 The Court is bound to follow the holding in *Transue*. That said, while  
6 comment *k* has application with respect to medical devices, it only applies when a  
7 product is “accompanied by adequate warnings.” *Taylor*, 187 Wash.2d at 764  
8 (quoting *Young v. Key Pharm., Inc.*, 130 Wash.2d 160, 184 (1996) (Madsen, J.,  
9 dissenting) (“Exemption from strict liability under comment *k* is expressly limited  
10 to products accompanied by *adequate warnings*. Stated another way—adequate  
11 warnings are a predicate to application of comment *k* by the express terms of the  
12 comment.”). Because genuine issues of material fact exist with respect to whether  
13 the warnings were adequate, the Court cannot say, as a matter of law, that  
14 summary judgment on Plaintiff’s strict liability design defect claim should be  
15 granted.<sup>3</sup>

16 //  
17 //  
18 //  
19 //  
20 //  
21 //

23 medical products recognize the unique protection provided to the consumers of  
24 such products by the prescribing physician (and/ or pharmacist) intermediary.” 141  
25 Wash.2d at 508.

26 <sup>3</sup> Moreover, even if comment *k* applies, this does not necessarily mean Plaintiff’s  
27 design defect claim must be dismissed. Rather, Washington law permits design  
28 defect claims based on a negligence standard. *See* WPJI 111.02.01.



1 Accordingly, **IT IS HEREBY ORDERED:**

2 1. Defendant's Motion for Summary Judgment, ECF No. 24, is  
3 **GRANTED**, in part; and **DENIED**, in part.

4 2. The following claims are dismissed: (Ct. I) Negligence; (Ct. III) Strict  
5 Liability – Manufacturing Defect; (Ct. V) Strict Liability – Defective Product; (Ct.  
6 VI) Breach of Express Warranty; (Ct. VII) Breach of Implied Warranty; (Ct. VIII)  
7 Fraudulent Concealment; (Ct. IX) Constructive Fraud; (Ct. X) Discovery Rule,  
8 Tolling and Fraudulent Concealment; (Ct. XI) Negligent Misrepresentation; (Ct.  
9 XII) Negligent Infliction of Emotional Distress; (Ct. XIII) Violation of Consumer  
10 Protection Law; (Ct. XIV) Gross Negligence; (Ct. XV) Unjust Enrichment; and  
11 (Ct. XVII) Punitive Damages.

12 **IT IS SO ORDERED.** The Clerk of Court is directed to enter this Order  
13 and forward copies to counsel.

14 **DATED** this 5th day of November 2020.

15  
16 

17  
18 Stanley A. Bastian  
19 U.S. District Judge  
20  
21  
22  
23  
24  
25  
26  
27  
28